Description

Aflac’s U.S. Growth Story Is Changing—Group Benefits Are Surging While Core Sales Lag!

Aflac Incorporated reported solid financial results for the fourth quarter and full year 2025, demonstrating steady operational performance in both its Japan and U.S. segments amidst a complex economic environment. The company recorded net earnings per diluted share of $2.64 in Q4 and $6.82 for 2025, with adjusted earnings per diluted share of $1.57 and $7.49, respectively. In Japan, Aflac Japan achieved a significant sales increase of 15.7% in the fourth quarter and 16% for the full year, driven primarily by the strong reception of Miraito, a cancer insurance product launched in March 2025, which saw a remarkable 35.6% sales uplift. The new medical product, Anshin Palette, also showed early positive market acceptance following its late-December introduction. Persistency remained robust at 93.1% for the year, despite lapses related to the Miraito launch, which is essential for offsetting future policy runoff and reinsurance impacts.